Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer.
Affiliation
Department of General Surgery, Manchester Royal Infirmary, St Mary's Hospital, Manchester, UK. emma.barrow@doctors.org.ukIssue Date
2008-07
Metadata
Show full item recordAbstract
BACKGROUND: Microsatellite instability (MSI) in colorectal cancer is caused by defective DNA mismatch repair (MMR). It is present in 15 per cent of sporadic colorectal cancers owing to epigenetic mutL homologue 1 (MLH1) inactivation. The evidence suggests that patients with tumours caused by defective DNA MMR do not benefit from 5-fluorouracil (5-FU)-based chemotherapy. METHODS: The proportion of cancers with defective DNA MMR identified by MSI analysis or immunohistochemistry was calculated from published data. The cost of analysis was compared with the potential savings if 5-FU-based chemotherapy was not administered to these patients. RESULTS: Some 16.3 per cent of sporadic colorectal cancers had defective DNA MMR. Immunostaining for MLH1 and mutS homologue 2 (MSH2) had a sensitivity of 92.4 per cent and a specificity of 99.6 per cent for identifying MSI-high tumours. The strongest predictive variable was right-sidedness, with positive and negative predictive values of 0.329 and 0.948 respectively. If 5-FU-based chemotherapy were not administered, potential savings of up to pound 1.2 million per 1000 patients tested could be made. Costs would be higher if alternative chemotherapeutic regimens were substituted as a result of testing. CONCLUSION: Knowledge of MMR status may enable participation in trials of non-5-FU-based chemotherapy. The cost of MMR testing may be offset by more efficient use of chemotherapy.Citation
Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. 2008, 95 (7):868-75 Br J SurgJournal
The British Journal of SurgeryDOI
10.1002/bjs.6172PubMed ID
18457354Type
ArticleLanguage
enISSN
1365-2168ae974a485f413a2113503eed53cd6c53
10.1002/bjs.6172
Scopus Count
Related articles
- Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
- Authors: Ohrling K, Edler D, Hallström M, Ragnhammar P
- Issue date: 2010 Aug
- Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
- Authors: Caldés T, Godino J, Sanchez A, Corbacho C, De la Hoya M, Lopez Asenjo J, Saez C, Sanz J, Benito M, Ramon Y Cajal S, Diaz-Rubio E
- Issue date: 2004 Sep
- Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
- Authors: Jensen LH, Lindebjerg J, Byriel L, Kolvraa S, Crüger DG
- Issue date: 2008 Jun
- Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
- Authors: Sheng JQ, Chan TL, Chan YW, Huang JS, Chen JG, Zhang MZ, Guo XL, Mu H, Chan AS, Li SR, Yuen ST, Leung SY
- Issue date: 2006
- An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
- Authors: Kim HR, Kim HC, Yun HR, Kim SH, Park CK, Cho YB, Yun SH, Lee WY, Chun HK
- Issue date: 2013 Nov